targetted inhalation therapies arikace late-stage clinical trialschronic pseudomonas ntm-lung-infections

  •  

Delivering novel,
targeted therapies
to improve the lives
of patients

suffering from serious
orphan lung diseases.

Learn More

Insmed and ARIKAYCE are registered trademarks in the United States and various other countries.

ARIKAYCEtm :

a novel inhalation therapy
designed to improve the
efficacy, safety, and
convenience of treatment.

 

Clinical trials are underway
in North America and Europe
as we prepare for regulatory filings
and commercialization.

 

 

70%of Adult
CF Patients
have acquired serious
chronic Pseudomonas
lung infections.

 

ARIKAYCE is in development for a
once-a-day treatment.

arikace nebulizer

 

 

Chronic, debilitating
NTM lung infections
are on the rise,

with no approved inhaled
antibiotics available.

 

ARIKAYCE is in development for a
once-a-day treatment.

arikace nebulizer

 

Investor Presentation

View the latest Insmed Investor Presentation here.

Learn More

Our Team

Insmed's mission is to improve the lives of patients battling serious orphan lung diseases through novel, targeted inhalation therapies in patient populations with critical unmet needs.

Learn More